Literature DB >> 24352705

Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis.

Jin Young Yoon1, Soo Jung Park, Sung Pil Hong, Tae Il Kim, Won Ho Kim, Jae Hee Cheon.   

Abstract

BACKGROUND: Accurate assessment of endoscopic severity is essential to the early detection of relapses and treatment of patients with ulcerative colitis (UC). However, the relationships between non-invasive biomarkers and invasive endoscopic severity indices remain poorly understood.
METHODS: A total of 722 endoscopies in 552 patients were evaluated in this study. Endoscopic activity was assessed using five widely used endoscopic scoring systems: the Powell-Tuck assessment, Mayo Endoscopic Score, modified Baron Score, Rachmilewitz Endoscopic Activity Index, and Hanauer's Sigmoidoscopic Index. These five indices were compared with two non-invasive biomarkers, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels.
RESULTS: The Pearson's correlation coefficients of CRP and ESR with endoscopic indices were r = 0.457 and 0.342 in the Powell-Tuck assessment, r = 0.503 and r = 0.402 in the Mayo Endoscopic Score, r = 0.507 and 0.408 in Hanauer's Sigmoidoscopic Index, r = 0.520 and 0.433 in the modified Baron Score, and r = 0.523 and 0.435 in the Rachmilewitz Endoscopic Activity Index. Sensitivity and specificity ranges for CRP and ESR were 50.5-53.3 % and 68.7-71.3 % and 85.1-87.2 % and 63.4-66.4 %, respectively, for the detection of endoscopic remission using the five endoscopic indices.
CONCLUSIONS: CRP and ESR levels were modestly correlated with endoscopic activity indices in UC patients. However, the low sensitivities for detecting endoscopic remission suggest that CRP or ESR alone is not sufficient to reflect endoscopic severity accurately.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24352705     DOI: 10.1007/s10620-013-2907-3

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  33 in total

1.  C-reactive protein reassessed.

Authors:  Alan R Tall
Journal:  N Engl J Med       Date:  2004-04-01       Impact factor: 91.245

2.  Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.

Authors:  Brian G Feagan; Gordon R Greenberg; Gary Wild; Richard N Fedorak; Pierre Paré; John W D McDonald; Rejean Dubé; Albert Cohen; A Hillary Steinhart; Steven Landau; Rasha A Aguzzi; Irving H Fox; Margaret K Vandervoort
Journal:  N Engl J Med       Date:  2005-06-16       Impact factor: 91.245

Review 3.  Diagnostics of inflammatory bowel disease.

Authors:  Susanna Nikolaus; Stefan Schreiber
Journal:  Gastroenterology       Date:  2007-11       Impact factor: 22.682

4.  Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.

Authors:  Jost Langhorst; Sigrid Elsenbruch; Julia Koelzer; Andreas Rueffer; Andreas Michalsen; Gustav J Dobos
Journal:  Am J Gastroenterol       Date:  2007-10-04       Impact factor: 10.864

5.  Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease.

Authors:  L S Kiss; T Szamosi; T Molnar; P Miheller; L Lakatos; A Vincze; K Palatka; Z Barta; B Gasztonyi; A Salamon; G Horvath; G T Tóth; K Farkas; J Banai; Z Tulassay; F Nagy; M Szenes; G Veres; B D Lovasz; Z Vegh; P A Golovics; M Szathmari; M Papp; P L Lakatos
Journal:  Aliment Pharmacol Ther       Date:  2011-08-24       Impact factor: 8.171

6.  [Comparative usefulness of erythrocyte sedimentation rate and C-reactive protein in assessing the severity of ulcerative colitis].

Authors:  Jung Su Ha; June Sang Lee; Hoi Jin Kim; Tae Gun Moon; Dong Kyung Chang; Jun Haeng Lee; Young Ho Kim; Poong Lyul Rhee; Jae J Kim; Jong Chul Rhee
Journal:  Korean J Gastroenterol       Date:  2006-11

7.  Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.

Authors:  D Rachmilewitz
Journal:  BMJ       Date:  1989-01-14

8.  Correlation of serum biomarkers with clinical severity and mucosal inflammation in Chinese ulcerative colitis patients.

Authors:  Ka Ho Lok; Chi Ho Ng; Hiu Gong Hung; Kam Fu Li; Kin Kong Li; Ming Leung Szeto
Journal:  J Dig Dis       Date:  2008-11       Impact factor: 2.325

9.  Correlation of serum-soluble triggering receptor expressed on myeloid cells-1 with clinical disease activity in inflammatory bowel disease.

Authors:  Jae Jun Park; Jae Hee Cheon; Bo Young Kim; Duk Hwan Kim; Eun Soo Kim; Tae Il Kim; Kyoung Ryul Lee; Won Ho Kim
Journal:  Dig Dis Sci       Date:  2008-10-31       Impact factor: 3.199

Review 10.  Laboratory markers in IBD: useful, magic, or unnecessary toys?

Authors:  S Vermeire; G Van Assche; P Rutgeerts
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

View more
  21 in total

Review 1.  Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease.

Authors:  Anet A Soubières; Andrew Poullis
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

2.  Monocytosis and a Low Lymphocyte to Monocyte Ratio Are Effective Biomarkers of Ulcerative Colitis Disease Activity.

Authors:  Cynthia E Cherfane; Luke Gessel; Dominic Cirillo; Miriam B Zimmerman; Steven Polyak
Journal:  Inflamm Bowel Dis       Date:  2015-08       Impact factor: 5.325

Review 3.  Mucosal Healing in Ulcerative Colitis: A Comprehensive Review.

Authors:  Pedro Boal Carvalho; José Cotter
Journal:  Drugs       Date:  2017-02       Impact factor: 9.546

4.  How useful are blood and stool biomarkers for detecting subclinical mucosal inflammation in ulcerative colitis?

Authors:  Byong Duk Ye
Journal:  Dig Dis Sci       Date:  2014-01-17       Impact factor: 3.199

Review 5.  Current best practice for disease activity assessment in IBD.

Authors:  Alissa J Walsh; Robert V Bryant; Simon P L Travis
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-01       Impact factor: 46.802

6.  [Improved Mayo Endoscopic Score has a higher value for evaluating clinical severity of ulcerative colitis].

Authors:  Z Song; M Zhang; Y Ren; B Iang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-07-20

Review 7.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Authors:  L Peyrin-Biroulet; W Sandborn; B E Sands; W Reinisch; W Bemelman; R V Bryant; G D'Haens; I Dotan; M Dubinsky; B Feagan; G Fiorino; R Gearry; S Krishnareddy; P L Lakatos; E V Loftus; P Marteau; P Munkholm; T B Murdoch; I Ordás; R Panaccione; R H Riddell; J Ruel; D T Rubin; M Samaan; C A Siegel; M S Silverberg; J Stoker; S Schreiber; S Travis; G Van Assche; S Danese; J Panes; G Bouguen; S O'Donnell; B Pariente; S Winer; S Hanauer; J-F Colombel
Journal:  Am J Gastroenterol       Date:  2015-08-25       Impact factor: 10.864

8.  Bowel ultrasound enhances predictive value based on clinical indicators: a scoring system for moderate-to-severe endoscopic activities in patients with ulcerative colitis.

Authors:  Mengmeng Zhang; Huimin Zhang; Qingli Zhu; Xiaoyin Bai; Qingyang Zhou; Gechong Ruan; Wenbo Li; Li Ma; Mengsu Xiao; Hong Yang; Jiaming Qian
Journal:  Therap Adv Gastroenterol       Date:  2021-07-13       Impact factor: 4.409

9.  Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis.

Authors:  Elham A Hassan; Haidi K Ramadan; Ali A Ismael; Khaled F Mohamed; Madiha M El-Attar; Ihab Alhelali
Journal:  Saudi J Gastroenterol       Date:  2017 Jul-Aug       Impact factor: 2.485

10.  Patient self-reported symptoms using visual analog scales are useful to estimate endoscopic activity in ulcerative colitis.

Authors:  Saya Tsuda; Reiko Kunisaki; Jun Kato; Mayu Murakami; Masafumi Nishio; Tsuyoshi Ogashiwa; Takeichi Yoshida; Hideaki Kimura; Masayuki Kitano
Journal:  Intest Res       Date:  2018-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.